Safety and efficacy of indigo naturalis for chronic enteropathy associated with SLCO2A1 and Cronkhite-Canada syndrome.
Not Applicable
- Conditions
- chronic enteropathy associated with SLCO2A1 and Cronkhite-Canada syndrome
- Registration Number
- JPRN-UMIN000025246
- Lead Sponsor
- Keio University Gastroenterology and Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
The patients who meet the following criteria are excluded. 1 The patients have stricture of the digestive tract. 2 The patients plans to undergo surgery. 3 The patients have severe infection. 4 The patients have severe heart failure. 5 The patients have serum Creatinine above 2. 6 The patients have T.Bil above 2.0, AST above 50, or ALT above 50. 7 The patients have malignancy or past history of malignancy. 8 The patients have neuropsychiatric disorder. 9 Women who are or may be pregnant, nursing women and woman who desire to bear children. 10 Inappropriate patients by doctor's judgement. 11 The patients who received other traditional chinese medicine inside 2 weeks.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety of indigo naturalis for chronic enteropathy associated with SLCO2A1 and Cronkhite-Canada syndrome after 24weeks
- Secondary Outcome Measures
Name Time Method efficacy of indigo naturalis for chronic enteropathy associated with SLCO2A1 and Cronkhite-Canada syndrome (endoscopic evaluation, clinical symptoms, Hb levels and serum Alb levels after 8 and 24 weeks)